Skip to main content
. 2021 Mar 26;16:2443–2459. doi: 10.2147/IJN.S289228

Figure 9.

Figure 9

Evaluation of the in vivo inhibition efficacy of treatment with saline, DOX, cetuximab, and cetuximab-vc-DOX-NPs. (A) Relative tumor volume of RKO tumor-bearing nude mice (n=6). (B) Survival rate of tumor-bearing mice in 38 days. (C) Body weight changes of tumor-bearing mice.